Residency · Residency · Geriatrics

Urinary Incontinence in Older Adults

Introduction

Urinary incontinence affects 30 to 50 percent of community-dwelling women and 15 to 30 percent of men aged 65 and older, with prevalence reaching 50 to 70 percent in long-term care settings. Despite these staggering numbers, urinary incontinence remains a geriatric syndrome that is profoundly underreported, with only 25 to 50 percent of affected individuals ever discussing the problem with their healthcare provider. This reticence stems from embarrassment, the erroneous belief that incontinence is a normal and inevitable consequence of aging, and inadequate screening by clinicians. Urinary incontinence is far from a benign condition: it is associated with falls, fractures, skin breakdown, urinary tract infections, social isolation, depression, caregiver burden, and institutionalization. The annual cost of urinary incontinence in the United States exceeds 65 billion dollars.

Age-Related Changes in the Lower Urinary Tract

Aging produces multiple physiological changes in the lower urinary tract that predispose to but do not independently cause incontinence. The detrusor muscle undergoes decreased contractile function and increased collagen deposition, and uninhibited detrusor contractions (detrusor overactivity) become more prevalent. Bladder capacity decreases from approximately 500 mL to 300 to 350 mL. Residual urine volume increases, with volumes up to 50 to 100 mL considered within the normal range for elderly individuals. In women, urethral closure pressure decreases as estrogen-dependent periurethral tissues atrophy. In men, prostate enlargement becomes nearly universal, with benign prostatic hyperplasia prevalence exceeding 50 percent at age 60 and 90 percent at age 80. Nocturnal polyuria develops as urine production shifts from daytime to nighttime due to decreased renal concentrating ability, increased atrial natriuretic peptide secretion, decreased antidiuretic hormone production, and nocturnal redistribution of peripheral edema. These age-related changes create a state of vulnerability in which additional precipitating factors, whether medical, pharmacological, or environmental, tip the balance toward clinical incontinence.

Classification

Transient (Reversible) Causes — DIAPPERS Mnemonic

The DIAPPERS mnemonic captures the major transient causes of urinary incontinence that should be addressed before any other intervention. Delirium impairs awareness of bladder signals and the ability to act on them. Infection (specifically symptomatic urinary tract infection; asymptomatic bacteriuria does not cause incontinence and should not be treated with antibiotics for this indication) produces irritative symptoms that worsen urgency. Atrophic vaginitis and urethritis from estrogen deficiency contribute to urethral incompetence and irritative symptoms. Pharmaceuticals represent a major category of reversible causes. Psychological conditions including severe depression and psychosis impair motivation and awareness. Excessive urine output from hyperglycemia, hypercalcemia, congestive heart failure, venous insufficiency, excessive fluid intake, or diuretic use overwhelms bladder capacity. Restricted mobility prevents timely access to the toilet. Stool impaction causes both detrusor overactivity and outlet obstruction through mechanical compression. Transient causes account for 30 to 50 percent of new-onset urinary incontinence in elderly patients and should always be addressed first.

Medication Causes

Multiple medication classes can cause or exacerbate urinary incontinence. Diuretics increase urine volume and urgency. Anticholinergic medications cause urinary retention leading to overflow incontinence. Alpha-blockers decrease urethral resistance and can precipitate stress incontinence in women. Alpha-agonists (decongestants) increase outlet resistance and can cause retention in men. Calcium channel blockers relax the detrusor (potentially causing retention) and produce peripheral edema that redistributes as nocturnal polyuria. Opioids cause urinary retention. Sedatives and hypnotics decrease awareness and impair mobility. Cholinesterase inhibitors increase detrusor contractility, producing urgency and frequency. ACE inhibitors can cause chronic cough that precipitates stress incontinence.

Established Types

Urgency Incontinence (Overactive Bladder — OAB)

Urgency incontinence is the most common type in elderly adults, accounting for 50 to 70 percent of cases. It is characterized by involuntary urine loss associated with a sudden, compelling desire to void that is difficult to defer. The underlying pathophysiology is detrusor overactivity, with involuntary detrusor contractions occurring during the bladder filling phase. It is associated with stroke, Parkinson disease, dementia, diabetes, and benign prostatic hyperplasia (where it develops secondary to outlet obstruction). Characteristic symptoms include frequency (more than 8 voids per day), urgency, nocturia (two or more episodes), and urge-related leakage.

Stress Incontinence

Stress incontinence is characterized by urine loss with physical exertion, coughing, sneezing, or laughing. It is more common in women due to pelvic floor weakness, urethral hypermobility, and intrinsic sphincter deficiency. Risk factors include vaginal deliveries, obesity, prior pelvic surgery, and estrogen deficiency. In men, stress incontinence typically occurs following prostatectomy as a result of sphincter injury.

Mixed Incontinence

Mixed incontinence, combining features of both urgency and stress incontinence, is the most common presentation in older women, affecting 30 to 40 percent of those with incontinence. Management should target the predominant component first.

Overflow Incontinence

Overflow incontinence results from an overdistended bladder and presents as continuous dribbling or frequent small-volume leakage. Causes include bladder outlet obstruction (benign prostatic hyperplasia, urethral stricture) and detrusor underactivity (from diabetes, spinal cord disease, or anticholinergic medications). A post-void residual volume exceeding 200 mL is characteristic.

Functional Incontinence

Functional incontinence occurs when the individual is unable to reach the toilet in time due to cognitive impairment, mobility limitations, or environmental barriers, despite a structurally and functionally normal urinary tract. It is common in hospitalized and institutionalized elderly patients. Management focuses on timed voiding, accessible commodes, mobility assistance, and appropriate clothing modifications.

<image>A diagnostic classification diagram for urinary incontinence in older adults. Show four quadrant panels, each illustrating a type of UI. Top-left: URGENCY — depict a bladder with involuntary detrusor contractions (wavy arrows on bladder wall), a clock showing high frequency, and a trigger (key turning in door as "latch-key urgency"). Top-right: STRESS — depict a bladder with weak pelvic floor support, arrows showing downward pressure from cough/sneeze, and urine leaking through an incompetent sphincter. Bottom-left: OVERFLOW — depict an overdistended bladder with high post-void residual volume, prostatic obstruction in men, and continuous dribbling. Bottom-right: FUNCTIONAL — depict a normal bladder but the patient in a wheelchair far from the bathroom with environmental barriers. Include the DIAPPERS mnemonic in a central box listing transient/reversible causes. Label each type with prevalence percentage and key clinical features.</image>

Evaluation

History

A thorough history begins with a three-day voiding diary (bladder diary) documenting timing and volume of voids, fluid intake, incontinence episodes, pad use, and triggers. Symptom characterization should distinguish urgency, frequency, nocturia, straining, incomplete emptying, and leakage with activity. In women, obstetric and gynecological history including parity, prior pelvic surgery, and estrogen status provides essential context. In men, prostate history including lower urinary tract symptom severity (IPSS score) and prior procedures is needed. Bowel habits should be assessed, as constipation and fecal incontinence are both associated with urinary incontinence. Functional and cognitive status, including mobility, ability to manage clothing, and cognitive capacity, directly affect management decisions. Fluid intake patterns (quantity, timing, caffeine and alcohol consumption) and a complete medication review for incontinence-causing drugs are essential components.

Physical Examination

Abdominal examination should assess for a palpable bladder (suggesting overflow incontinence) and suprapubic tenderness. Pelvic examination in women should evaluate vaginal atrophy, pelvic organ prolapse (using POP-Q staging), urethral hypermobility (Q-tip test), and should include a cough stress test with direct visualization of leakage. Rectal examination should assess prostate size and nodularity in men, rectal tone, fecal impaction, and perianal sensation (testing the S2 to S4 dermatomes). Neurological examination should assess lower extremity strength, sensation, and reflexes, with attention to saddle anesthesia suggesting cauda equina involvement. Functional assessment should include observed gait, ability to rise from a chair, and ability to manage clothing.

Diagnostic Studies

Urinalysis should be performed to evaluate for hematuria (which may indicate bladder cancer), infection, and glycosuria. Post-void residual volume measurement using an ultrasound bladder scanner is preferred; a volume exceeding 200 mL suggests overflow incontinence, and volumes exceeding 300 mL warrant further evaluation. A basic metabolic panel assessing glucose, calcium, and renal function is appropriate. Urodynamic studies are not routine for initial evaluation and are reserved for patients who have failed empiric treatment, who have an uncertain diagnosis after initial workup, who are being evaluated for surgery, or who have complex neurological conditions. Cystoscopy is indicated for hematuria, recurrent urinary tract infections, or suspected bladder pathology. Renal ultrasonography is obtained when upper tract pathology is suspected.

Management

Behavioral and Lifestyle Interventions (First-Line for All Types)

Pelvic Floor Muscle Training (PFMT) — Kegel Exercises

Pelvic floor muscle training is the first-line intervention for stress and mixed urinary incontinence and is also effective for urgency incontinence. The technique involves identifying and contracting the pelvic floor muscles (as if stopping the urine stream), holding for 5 to 10 seconds, relaxing for 10 seconds, and repeating for 10 to 15 contractions in three sets per day. Supervised training with biofeedback is significantly more effective than written instructions alone. A Cochrane review demonstrated that pelvic floor muscle training cured or improved incontinence in 56 to 74 percent of women compared to 20 percent with no treatment. Patients should be counseled that benefit requires 6 to 12 weeks to become apparent.

Bladder Training (for Urgency UI)

Bladder training involves scheduled voiding with progressive increases in the interval between voids. The starting interval matches the patient's current voiding frequency (typically every 1 to 2 hours), and this interval is increased by 15 to 30 minutes weekly toward a goal of 3- to 4-hour voiding intervals. Urgency suppression techniques, including quick pelvic floor contractions, distraction, and standing still until the urge passes, are integral components. Bladder training reduces incontinence episodes by 50 to 80 percent.

Prompted Voiding (for Cognitively Impaired)

Prompted voiding is a caregiver-dependent technique in which the caregiver checks the patient regularly (every 2 hours), asks about wetness or the need to void, and prompts toileting. It is most effective in patients who can ambulate or transfer and who retain some awareness of bladder signals. This approach reduces incontinence episodes by 30 to 40 percent in nursing home residents.

Timed Voiding/Habit Training

Timed voiding involves voiding on a fixed schedule (every 2 to 3 hours) regardless of urge. It is simpler than prompted voiding and is suitable for more cognitively impaired individuals.

Lifestyle Modifications

Fluid management should target adequate hydration (1.5 to 2 liters per day) while avoiding excessive intake and limiting evening fluids for patients with nocturia. Caffeine reduction decreases urgency and frequency. Weight loss of 5 to 10 percent reduces stress incontinence episodes by approximately 50 percent, as demonstrated in the PRIDE trial where 8 percent weight loss produced a 47 percent reduction. Constipation management and smoking cessation (chronic cough exacerbates stress incontinence) complement these behavioral approaches.

Pharmacological Treatment

Urgency Incontinence / OAB

Antimuscarinic (anticholinergic) medications have historically been the mainstay of pharmacological treatment for urgency incontinence, but their use in elderly patients is fraught with safety concerns. Oxybutynin in its immediate-release formulation (2.5 to 5 mg two to three times daily) should be avoided in elderly patients due to its high anticholinergic burden, central nervous system penetration, and propensity to cause cognitive impairment. Extended-release formulations and topical preparations (gel or patch) produce fewer systemic anticholinergic effects but still carry risk. Tolterodine extended-release (4 mg daily) is better tolerated than oxybutynin but remains anticholinergic. Trospium extended-release (60 mg daily), as a quaternary amine that does not cross the blood-brain barrier, is the preferred antimuscarinic in elderly patients when one must be used. All antimuscarinic agents are listed in the Beers Criteria as potentially inappropriate for elderly patients and must be avoided in patients with dementia or cognitive impairment. Gray and colleagues demonstrated in 2015 that cumulative anticholinergic exposure was associated with increased dementia risk, with a hazard ratio of 1.54 for three or more years of use.

Beta-3 adrenergic agonists are the preferred pharmacotherapy for urgency incontinence in elderly patients. Mirabegron (25 to 50 mg daily) activates beta-3 adrenergic receptors on the detrusor muscle, promoting relaxation without any anticholinergic activity. Vibegron (75 mg daily) is a more selective beta-3 agonist. These agents carry no cognitive risk, making them clearly superior to antimuscarinics in elderly populations. Side effects include hypertension (blood pressure should be monitored), urinary tract infection, headache, and nasopharyngitis. Combination therapy with a low-dose antimuscarinic agent can be considered for refractory cases, as demonstrated in the SYNERGY trial.

Stress Incontinence

No medication is FDA-approved for stress urinary incontinence. Duloxetine, used off-label at 40 to 80 mg daily, increases urethral sphincter tone via pudendal nerve stimulation but causes nausea, dizziness, and fatigue. Topical vaginal estrogen improves urethral mucosal coaptation and reduces recurrent urinary tract infections without producing significant systemic estrogen levels. Available formulations include estradiol cream, vaginal ring (Estring), and vaginal tablet (Vagifem/Yuvafem), all of which are considered safe even in women with a history of breast cancer given their minimal systemic absorption.

Nocturia

Management of nocturia should begin with addressing underlying causes: congestive heart failure (nocturnal diuresis), peripheral edema (which can be managed with an afternoon diuretic and leg elevation), sleep apnea, and excessive evening fluid intake. Desmopressin (DDAVP), while available for nocturnal polyuria, should be avoided in elderly patients aged 65 and older due to the significant risk of hyponatremia, which carries an FDA boxed warning for this indication. Timed afternoon administration of a diuretic such as furosemide 20 mg at 4 PM can reduce nocturia caused by peripheral edema redistribution.

<image>A treatment algorithm for urinary incontinence in older adults. Show a central starting point "UI confirmed by evaluation" branching into four pathways by type. URGENCY UI pathway: behavioral therapy (bladder training + PFMT) as first-line → if inadequate, add beta-3 agonist (mirabegron or vibegron, highlighted as PREFERRED in elderly) → if still inadequate, consider adding low-dose antimuscarinic (with warning symbol for cognitive risk) or refer for advanced therapies (botox, PTNS, sacral neuromodulation). STRESS UI pathway: PFMT with biofeedback as first-line → vaginal estrogen if atrophic → if severe, surgical referral (midurethral sling, colposuspension). OVERFLOW UI pathway: address obstruction (alpha-blocker for BPH or catheterization) → intermittent catheterization if detrusor underactivity. FUNCTIONAL UI pathway: timed voiding, prompted voiding, environmental modifications (bedside commode, clothing adaptations). Include a red warning box for antimuscarinics: "AVOID oxybutynin and high-anticholinergic agents in elderly — use beta-3 agonists as preferred pharmacotherapy."</image>

Surgical and Procedural Options

For Urgency/OAB (Refractory to Conservative Management)

OnabotulinumtoxinA (Botox) at 100 units injected cystoscopically into the detrusor reduces incontinence episodes by 50 percent with a duration of effect of 6 to 9 months, repeated as needed. The principal risks are urinary retention (6 percent) and urinary tract infection (15 to 30 percent), and patients must be willing and able to perform self-catheterization if retention occurs. Percutaneous tibial nerve stimulation involves weekly 30-minute sessions for 12 weeks followed by monthly maintenance, achieving a 54 to 80 percent response rate. Sacral neuromodulation (InterStim) uses an implanted neurostimulator and achieves 70 to 80 percent response, reserved for refractory cases.

For Stress UI

The midurethral sling is the gold standard surgical treatment for female stress urinary incontinence, with an 80 to 90 percent cure rate. Colposuspension (Burch procedure) performed laparoscopically or open is an alternative. Urethral bulking agents offer a less invasive option with lower cure rates and may require repeat injections. For male stress incontinence following prostatectomy, the artificial urinary sphincter is the gold standard, with male slings available for mild-to-moderate cases.

Containment Products

Absorbent products (pads, briefs) should be appropriately sized and changed frequently with attention to skin protection. External collection devices, including condom catheters for men, carry lower urinary tract infection risk than indwelling catheters; female external devices are an emerging option. Indwelling urethral catheters should be considered the absolute last resort, as they are associated with universal bacteriuria by 30 days, urinary tract infection, urethral erosion, and bladder stones. Their use is appropriate only for acute urinary retention, wound contamination prevention, comfort at end of life, or patient preference when all other options have been exhausted.

Key Clinical Pearls

• Always rule out transient causes first (DIAPPERS) — they account for 30-50% of new-onset UI in elderly and are often reversible
• AVOID oxybutynin and other high-anticholinergic bladder medications in elderly — beta-3 agonists (mirabegron, vibegron) are preferred pharmacotherapy for urgency UI with no cognitive risk
• Behavioral therapies (PFMT, bladder training) are first-line for ALL types of UI and are at least as effective as medications without side effects — they take 6-12 weeks to work
• Asymptomatic bacteriuria does NOT cause incontinence and should NOT be treated with antibiotics
• Nocturia in the elderly is most commonly due to nocturnal polyuria from cardiac/venous causes — not OAB; treat with leg elevation and afternoon diuretic, not antimuscarinics
• Indwelling catheters are associated with nearly universal bacteriuria by 30 days — avoid unless absolutely necessary
• Weight loss of 5-10% reduces stress UI episodes by nearly 50% — it is one of the most effective interventions available

References

1. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592-1604.
2. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558-563.
3. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401-407.
4. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10:CD005654.
5. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481-490.

Read this lecture as Markdown